CRESCENT BIOPHARMA, INC. Income Statement
CBIO|5 years of annual SEC 10-K data (FY2014-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
CRESCENT BIOPHARMA, INC. reported $11M in revenue and $154M in net loss for FY2025. Revenue has declined at a 3.1% compound annual rate over the past 11 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | $10.8M | $20.1M | $15.0M | $4.0M | $15.3M |
| SG&A Expense | $25.4M | $7.8M | $6.6M | $2.9M | $2.2M |
| R&D Expense | $138.1M | $25.1M | $19.6M | $11.7M | $9.4M |
| Operating Income | -$152.6M | -$12.8M | -$11.1M | -$10.6M | $3.6M |
| Income Tax | $2.0M | - | - | - | - |
| Net Income | -$153.9M | -$12.8M | -$11.1M | -$10.6M | $3.7M |
| EPS (Basic) | - | - | - | -$0.37 | $3.93 |
| EPS (Diluted) | - | -$0.67 | -$0.60 | -$0.37 | $0.33 |
| Shares Outstanding | 1.0M | 23.3M | 19.1M | 18.9M | 1.4M |
| Operating Margin | -1407.5% | -63.7% | -74.1% | -265.6% | 23.8% |
| Profit Margin | -1419.6% | -63.6% | -74.0% | -265.6% | 24.0% |